Show simple item record

dc.contributor.authorGuo, J
dc.contributor.authorJin, J
dc.contributor.authorOya, M
dc.contributor.authorUemura, H
dc.contributor.authorTakahashi, S
dc.contributor.authorTatsugami, K
dc.contributor.authorRha, SY
dc.contributor.authorLee, J-L
dc.contributor.authorChung, J
dc.contributor.authorLim, HY
dc.contributor.authorWu, HC
dc.contributor.authorChang, YH
dc.contributor.authorAzad, A
dc.contributor.authorDavis, ID
dc.contributor.authorCarrasco-Alfonso, MJ
dc.contributor.authorNanua, B
dc.contributor.authorHan, J
dc.contributor.authorAhmad, Q
dc.contributor.authorMotzer, R
dc.date.accessioned2020-12-17T04:06:23Z
dc.date.available2020-12-17T04:06:23Z
dc.date.issued2018-05-22
dc.identifierpii: 10.1186/s13045-018-0617-1
dc.identifier.citationGuo, J., Jin, J., Oya, M., Uemura, H., Takahashi, S., Tatsugami, K., Rha, S. Y., Lee, J. -L., Chung, J., Lim, H. Y., Wu, H. C., Chang, Y. H., Azad, A., Davis, I. D., Carrasco-Alfonso, M. J., Nanua, B., Han, J., Ahmad, Q. & Motzer, R. (2018). Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. JOURNAL OF HEMATOLOGY & ONCOLOGY, 11 (1), https://doi.org/10.1186/s13045-018-0617-1.
dc.identifier.issn1756-8722
dc.identifier.urihttp://hdl.handle.net/11343/255163
dc.description.abstractBACKGROUND: The international, phase 3 COMPARZ study demonstrated that pazopanib and sunitinib have comparable efficacy as first-line therapy in patients with advanced renal cell carcinoma, but that safety and quality-of-life profiles favor pazopanib. Our report analyzed pazopanib and sunitinib safety in Asian and non-Asian subpopulations. METHODS: Patients were randomized 1:1 to receive pazopanib 800 mg once daily (continuous dosing) or sunitinib 50 mg once daily in 6-week cycles (4 weeks on, 2 weeks off). RESULTS: Safety population was composed of 363 Asian patients and 703 non-Asian patients. Asian patients had similar duration of exposure to either drug compared with non-Asian patients, although Asian patients had a higher frequency of dose modifications. Overall, hematologic toxicities, cytopenias, increased AST/ALT, and palmar-plantar erythrodysesthesia (PPE) were more prevalent in Asian patients, whereas gastrointestinal toxicities were more prevalent in non-Asian patients. Among Asian patients, hematologic adverse events and most non-hematologic AEs were more common in sunitinib-treated versus pazopanib-treated patients. Among Asian patients, the most common grade 3/4 AEs with pazopanib were hypertension (grade 3, 22%) and alanine aminotransferase increased (grade 3, 12%; grade 4, 1%); the most common grade 3/4 AEs with sunitinib were thrombocytopenia/platelet count decreased (grade 3, 36%; grade 4, 10%), neutropenia/neutrophil count decreased (grade 3, 24%; grade 4, 3%) hypertension (grade 3, 20%), and PPE (grade 3, 15%). CONCLUSIONS: A distinct pattern and severity of adverse events was observed in Asians when compared with non-Asians with both pazopanib and sunitinib. However, the two drugs were well tolerated in both subpopulations. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00720941 , Registered July 22, 2008 ClinicalTrials.gov, NCT01147822 , Registered June 22, 2010.
dc.languageEnglish
dc.publisherBIOMED CENTRAL LTD
dc.titleSafety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
dc.typeJournal Article
dc.identifier.doi10.1186/s13045-018-0617-1
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.affiliation.departmentMedicine and Radiology
melbourne.source.titleJournal of Hematology and Oncology
melbourne.source.volume11
melbourne.source.issue1
dc.rights.licenseCC BY
melbourne.elementsid1330867
melbourne.contributor.authorAzad, Arun
melbourne.contributor.authorDavis, Ian
dc.identifier.eissn1756-8722
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record